Showing results (761-770 of 3,353) with videos related to
Sort By:
Pageof 336
The Lancet. Oncology|November 16, 2024
Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trialJean-Marc Classe, Pierre Meeus, Delphine Hudry, et al.The Lancet. Oncology|November 18, 2024
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trialGiovanni Randon, Sara Lonardi, Matteo Fassan, et al.The Lancet. Oncology|December 5, 2024
Navigating the oncology drug discovery and development process with programmes supported by the National Institutes of HealthOluwatobi T Arisa, Erica L Beatson, Annieka Reno, et al.The Lancet. Oncology|March 6, 2025
Cancer surveillance in the Eastern Mediterranean region: a 10-year International Agency for Research on Cancer-WHO Regional Office for the Eastern Mediterranean collaborationAriana Znaor, Heba Fouad, Mariam Zahwe, et al.The Lancet. Oncology|October 22, 2024
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysisAntonio D'Alessio, Bernardo Stefanini, Julia Blanter, et al.The Lancet. Oncology|October 3, 2024
The tyranny of non-inferiority trialsIan F Tannock, Marc Buyse, Mickael De Backer, et al.The Lancet. Oncology|October 3, 2024
Challenges and opportunities for early phase clinical trials of novel drug-radiotherapy combinations: recommendations from NRG Oncology, the American Society for Radiation Oncology (ASTRO), the American College of Radiology (ACR), the Sarah Cannon Research Institute, and the American College of Radiation Oncology (ACRO)Zachary S Zumsteg, Siddharth Sheth, Salma K Jabbour, et al.The Lancet. Oncology|August 10, 2024
Cancer incidence and survival for 11 cancers in the Commonwealth: a simulation-based modelling studyZachary J Ward, Qassi Gaba, Rifat AtunThe Lancet. Oncology|August 12, 2024
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trialPierre Vera, Sébastien Thureau, Florence Le Tinier, et al.The Lancet. Oncology|August 1, 2024
Radiotherapy, immunity, and immune checkpoint inhibitorsConnor Lynch, Sean P Pitroda, Ralph R WeichselbaumPageof 336